# Duration of Ameluz Application in Acral Actinic Keratoses Response

> **NCT03963102** · PHASE4 · TERMINATED · sponsor: **Royal Cornwall Hospitals Trust** · enrollment: 28 (actual)

## Conditions studied

- Actinic Keratoses
- Photodamaged Skin

## Interventions

- **DRUG:** Ameluz

## Key facts

- **NCT ID:** NCT03963102
- **Lead sponsor:** Royal Cornwall Hospitals Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-30
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Lack of appropriate personnel. Dr Xie abroad on other research, current PI Dr John Frewen not at main centre, no other available PI identified. Study suspended.
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03963102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03963102, "Duration of Ameluz Application in Acral Actinic Keratoses Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03963102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*